Search

Your search keyword '"Yoon, In-Soo"' showing total 5,910 results
Start Over Author "Yoon, In-Soo"
5,910 results on '"Yoon, In-Soo"'

1. Pulse shape discrimination in an organic scintillation phoswich detector using machine learning techniques

Author

Lee, Yujin, Kim, Jinyoung, Koh, Byoung-cheol, Yoon, Young Soo, and Ha, Chang Hyon

Subjects
Physics - Instrumentation and Detectors, Astrophysics - Instrumentation and Methods for Astrophysics, High Energy Physics - Experiment
Abstract

We developed machine learning algorithms for distinguishing scintillation signals from a plastic-liquid coupled detector known as a phoswich. The challenge lies in discriminating signals from organic scintillators with similar shapes and short decay times. Using a single-readout phoswich detector, we successfully identified $\gamma$ radiation signals from two scintillating components. Our Boosted Decision Tree algorithm demonstrated a maximum discrimination power of 3.02 $\pm$ 0.85 standard deviation in the 950 keV region, providing an efficient solution for self-shielding and enhancing radiation detection capabilities., Comment: 11pages, 7 figures

Published
2024

9. Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Chemotherapy.

Author

Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Recher, Christian, Yoon, Sung-Soo, Maeda, Yoshinobu, Hosono, Naoko, Onozawa, Masahiro, Kato, Takayasu, Kim, Hee-Je, Hasabou, Nahla, Nuthethi, Rishita, Tiu, Ramon, Levis, Mark, Perl, Alexander, Larson, Richard, Podoltsev, Nikolai, Strickland, Stephen, Wang, Eunice, Atallah, Ehab, and Schiller, Gary

Subjects
Acute myelogenous leukemia, FLT3 inhibitor, FLT3 mutation, Hematopoietic stem cell transplantation, Post-transplantation maintenance therapy, Adult, Humans, fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Aniline Compounds, Recurrence
Abstract

The fms-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib improved the survival of patients with relapsed or refractory (R/R) FLT3-mutated acute myelogenous leukemia (AML) in the phase 3 ADMIRAL trial. In this study, we assessed survival and relapse rates of patients in the ADMIRAL trial who underwent hematopoietic stem cell transplantation (HSCT), as well as safety outcomes in patients who received post-transplantation gilteritinib maintenance therapy. ADMIRAL was a global phase 3 randomized controlled trial that enrolled adult patients with FLT3-mutated R/R AML. Patients with R/R AML who harbored FLT3 internal tandem duplication mutations in the juxtamembrane domain or D835/I836 point mutations in the tyrosine kinase domain were randomized (2:1) to gilteritinib (120 mg/day) or to preselected high- or low-intensity salvage chemotherapy (1 or 2 cycles). Patients in the gilteritinib arm who proceeded to HSCT could receive post-transplantation gilteritinib maintenance therapy if they were within 30 to 90 days post-transplantation and had achieved composite complete remission (CRc) with successful engraftment and no post-transplantation complications. Adverse events (AEs) during HSCT were recorded in the gilteritinib arm only. Survival outcomes and the cumulative incidence of relapse were assessed in patients who underwent HSCT during the trial. Treatment-emergent AEs were evaluated in patients who restarted gilteritinib as post-transplantation maintenance therapy. Patients in the gilteritinib arm underwent HSCT more frequently than those in the chemotherapy arm (26% [n = 64] versus 15% [n = 19]). For all transplantation recipients, 12- and 24-month overall survival (OS) rates were 68% and 47%, respectively. Despite a trend toward longer OS after pretransplantation CRc, post-transplantation survival was comparable in the 2 arms. Patients who resumed gilteritinib after HSCT had a low relapse rate after pretransplantation CRc (20%) or CR (0%). The most common AEs observed with post-transplantation gilteritinib therapy were increased alanine aminotransferase level (45%), pyrexia (43%), and diarrhea (40%); grade ≥3 AEs were related primarily to myelosuppression. The incidences of grade ≥III acute graft-versus-host disease and related mortality were low. Post-transplantation survival was similar across the 2 study arms in the ADMIRAL trial, but higher remission rates with gilteritinib facilitated receipt of HSCT. Gilteritinib as post-transplantation maintenance therapy had a stable safety and tolerability profile and was associated with low relapse rates. Taken together, these data support a preference for bridging therapy with gilteritinib over chemotherapy in transplantation-eligible patients.

Published
2023

18. Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials

Author

Dixon, Bradley P., Kavanagh, David, Aris, Alvaro Domingo Madrid, Adams, Brigitte, Kang, Hee Gyung, Wang, Edward, Garlo, Katherine, Ogawa, Masayo, Amancha, Praveen, Chakravarty, Sourish, Heyne, Nils, Kim, Seong Heon, Cataland, Spero, Yoon, Sung-Soo, Miyakawa, Yoshitaka, Luque, Yosu, Muff-Luett, Melissa, Tanaka, Kazuki, and Greenbaum, Larry A.

Published
2024
Full Text
View/download PDF

37. Genetic assessment of pathogenic germline alterations in lysosomal genes among Asian patients with pancreatic ductal adenocarcinoma

Author

Koh, Youngil, Kim, Hyemin, Joo, So Young, Song, Seulki, Choi, Young Hoon, Kim, Hyung Rae, Moon, Byul, Byun, Jamin, Hong, Junshik, Shin, Dong-Yeop, Park, Solip, Lee, Kwang Hyuck, Lee, Kyu Taek, Lee, Jong Kyun, Park, Daechan, Lee, Se-Hoon, Jang, Jin-Young, Lee, Hyunsook, Kim, Jung-Ae, Yoon, Sung-Soo, and Park, Joo Kyung

Published
2023
Full Text
View/download PDF

40. Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation

Author

Baek, Dong Won, Moon, Joon Ho, Lee, Jae Hoon, Kang, Ka-Won, Lee, Ho Sup, Eom, Hyeon-Seok, Lee, Enuyoung, Lee, Ji Hyun, Lee, Jeong-Ok, Park, Seong Kyu, Kim, Seok Jin, Yoo, Keon Hee, Yoon, Sung-Soo, Koh, Youngil, Kang, Hyoung Jin, Won, Jong-Ho, Lyu, Chuhl Joo, Hahn, Seung Min, Lee, Jung-Hee, Park, Joon Seong, Jo, Jae-Cheol, Mun, Yeung-Chul, Yang, Deok-Hwan, Song, Ga-Young, Lim, Sung-Nam, and Sohn, Sang Kyun

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results